Sucralfate is a medication used to treat stomach ulcers and gastroesophageal reflux disease. It works by forming a protective coating over the damaged area of the stomach or esophagus, allowing it to heal. It can be taken orally as tablets or suspensions. Sucralfate is also used to protect the stomach during treatments with NSAIDs.

The global sucralfate market is estimated to be valued at US$ 60.8 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the key drivers for the growth of the U.S. sucralfate market size is the rising incidences of peptic ulcers in the country. According to the American College of Gastroenterology, approximately 5 million Americans are diagnosed with peptic ulcers each year. Sucralfate is widely used in the treatment of peptic ulcers due to its protective effects on the stomach. Additionally, increasing prevalence of gastroesophageal reflux disease (GERD) is also fueling the demand for sucralfate in the U.S. GERD affects approximately 20% of the U.S. population and sucralfate provides relief from the discomfort caused by GERD by forming a protective coating on the esophagus.

SWOT Analysis
Strength: Sucralfate has excellent binding affinity to ulcer sites and forms an ulcer-protective complex. It demonstrates efficacy in relieving pain and promoting healing of ulcers. The drug shows few systemic absorptions and side effects are generally mild.
Weakness: Sucralfate requires frequent administration as it has a short residence time at ulcer sites. Patient compliance can be a challenge due to its four times a day dosing schedule. The suspension formulation has poor palatability which may reduce patient acceptance.
Opportunity: The growing prevalence of peptic ulcers and gastrointestinal disorders in the geriatric population presents an opportunity for sucralfate manufacturers. Expanding indications of sucralfate to erosive esophagitis and other ulcer conditions can further stimulate the market.
Threats: Low drug adherence and compliance rates pose a major threat. Alternative drugs like PPIs are widely used first line therapies for peptic ulcers threatening sucralfate usage. Rising healthcare costs and price competition from generic drugs can impact profitability.

Key Takeaways
The U.S. sucralfate market is expected to witness high growth over the forecast period aided by rising ulcer disease burden. The global sucralfate market is estimated to be valued at US$ 60.8 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.

The region accounts for over 35% of the global sucralfate market currently dominated by key players. Regional analysis indicates that the South region holds the highest market share currently attributed to growing elderly population and higher disease prevalence. However, the Northeast region is poised to exhibit fastest growth driven by rising healthcare spending and adoption of new drugs.

Key players operating in the U.S. sucralfate market are Shire, Apotex, Mylan Pharmaceuticals, and Aurobindo Pharma. Shire holds the leading market share with its sucralfate suspension brand Carafate while Mylan offers a sucralfate tablet formulation. These companies are focusing on expanding sucralfate indications and developing novel drug delivery systems to improve patient compliance and convenience. The market is expected to be further competitive with the entry of generic versions post patent expiration of brand drugs in late 2020s.

Get more insights on this topic: https://www.trendingwebwire.com/sucralfate-market-size-and-outlook/